Condition (MeSH)
Osteolysis
ClinicalTrials.gov lists 27 trials for Osteolysis or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
21 of the 27 trials are tagged with Osteolysis itself; the rest are tagged with a narrower condition beneath it.
When did Osteolysis trials start? (18)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Phase 4
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 2 |
| 2023 | 2 |
| 2022 | 1 |
| 2021 | 3 |
| 2019 | 1 |
| 2016 | 1 |
| 2015 | 3 |
| 2013 | 1 |
| 2012 | 1 |
Showing 10 of 18 earlier years.
No forecast is made for this condition: it averages 1.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 27 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Osteolysis trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 3 |
| Phase 4 | 1 |
| Not applicable | 8 |
| Observational | 15 |
How many Osteolysis trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 4 |
| Active, not recruiting | 2 |
| Completed | 11 |
| Terminated | 1 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Osteolysis trials? (6)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Aesculap AG | 1 |
| Bayer | 1 |
| Encore Medical, L.P. | 1 |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 1 |
| IC-MedTech Corporation | 1 |
Showing 5 of 6 sponsors.
Which drugs are being tested for Osteolysis? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| SCLEROSTIN | 1 |
| DENOSUMAB | 1 |
Interventions as named in the registry (6)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Apatone®B | 1 |
| ARQ197 | 1 |
| Control (placebo) group | 1 |
| acid Zoledronic | 1 |
| Exercise | 1 |
Showing 5 of 6 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Osteolysis trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Revision for any reason other than aseptic loosening | 13 | 1 |
| Wear/Osteolysis without fracture | 10 | 1 |
| Revision due to Wear/Osteolysis | 9 | 1 |
| Revision for aseptic loosening | 7 | 1 |
| Wear/Osteolysis with Fracture | 7 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Osteolysis? (117)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Denosumab for treating periprosthetic osteolysis: a feasibility study. | BMC research notes | 2025 | Yes |
| MRI-based Zero Echo Time and Black Bone Pseudo-CT Compared with Whole-Body CT to Detect Osteolytic Lesions in Multiple Myeloma. | Radiology | 2024 | Yes |
| Titanium particles in peri-implantitis: distribution, pathogenesis and prospects. | International journal of oral science | 2023 | Yes |
| The use of acetabular screws in total hip arthroplasty and its influence on wear and periacetabular osteolysis in the long-term follow-up. | International orthopaedics | 2022 | Yes |
| Rapidly Destructive Hip Disease Following Intra-Articular Corticosteroid Injection of the Hip. | The Journal of bone and joint surgery. American volume | 2021 | Yes |
Showing 5 of 117 publications.
Sub-conditions in MeSH (2)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.